This approval by the EC was based on results from the Phase 3 OlympiA trial and follows the recommendation for approval of LYNPARZA in this setting by the
(C) 2022 Electronic News Publishing, source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
127.1 USD | +0.14% | +1.59% | +16.54% |
This approval by the EC was based on results from the Phase 3 OlympiA trial and follows the recommendation for approval of LYNPARZA in this setting by the
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+16.54% | 322B | |
+27.25% | 659B | |
+27.68% | 557B | |
-4.20% | 359B | |
+9.83% | 297B | |
+6.30% | 215B | |
+4.80% | 210B | |
-6.05% | 200B | |
-8.79% | 149B | |
-4.87% | 146B |